Brief: Marinus Pharmaceuticals Reports Preliminary Fourth Quarter And Full Year 2022 Ztalmy® Net Product Revenue And Provides Business Update

Marinus Pharmaceuticals

05/01/2023 22:03

Jan 5 (Reuters) - Marinus Pharmaceuticals Inc  MRNS.O :
    * MARINUS PHARMACEUTICALS REPORTS PRELIMINARY FOURTH QUARTER
AND
FULL YEAR 2022 ZTALMY® NET PRODUCT REVENUE AND PROVIDES BUSINESS
UPDATE
    * MARINUS PHARMACEUTICALS - OVER 90 TOTAL COMPLETED CDD
PRESCRIPTION ENROLLMENT FORMS RECEIVED AS OF DEC 31, 2022
    * MARINUS PHARMACEUTICALS INC - PRELIMINARY UNAUDITED NET
PRODUCT
REVENUE OF BETWEEN $2.2 AND $2.3 MILLION FOR Q4 OF 2022
    * MARINUS - MORE THAN 75% OF CDD PATIENTS WITH COMPLETED
PRESCRIPTION ENROLLMENT FORMS WERE ABLE TO RECEIVE REIMBURSED
THERAPY BY END OF Q4 OF 2022
    * MARINUS PHARMACEUTICALS INC - CONTINUE TO TARGET TOPLINE
DATA
FOR ONGOING PHASE 3 TRIALS IN REFRACTORY STATUS EPILEPTICUS IN
SECOND HALF OF 2023
    * MARINUS PHARMACEUTICALS INC - CONTINUE TO TARGET TOPLINE
DATA
FOR ONGOING PHASE 3 TRIALS IN  TUBEROUS SCLEROSIS COMPLEX IN Q1
OF 2024
    * MARINUS PHARMACEUTICALS INC - SECOND GENERATION
FORMULATION
PROGRAM CONTINUES TO ADVANCE WITH AN UPDATE PLANNED IN Q1 OF
2023

Source text for Eikon:  ID:nBw4R50R3a 
Further company coverage:  MRNS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))